SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas SpaceX-thruster Roadster demonstration sparked debate, but traders largely focused on the stocks sharp fade after initial enthusiasm, questioning whether the prototype has practical or meaningful near-term earnings value; broader tech weakness also weighed. Some traders speculated the event could foreshadow a TeslaSpaceX merger, but no deal has been announced.

USA Rare Earth, Inc. is a domestic supplier of rare earth magnets and heavy rare earth elements. It develops a vertically integrated domestic supply chain for rare earth element magnet production, with a facility in Stillwater and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USAR is drawing attention amid a prolonged selloff that traders link to weakness across rare-earth stocks, alongside concerns about potential share dilution, heavy spending before production scales, and limited near-term revenue. Bulls point to government backing and the strategic push for domestic rare-earth supply, while bears question execution and whether that long-term promise can offset near-term financing and operating risks.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS shares sold off sharply on heavy volume without a company-specific update, with traders pointing to a broader biotech downturn and options-expiration pressure around the $10 strike. The move fueled debate over possible market mechanics versus concern about the prolonged quiet period and the pending 80th-event milestone and REGAL Phase 3 data; many holders treated the drop as a buying opportunity while others questioned managements silence.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOI is drawing attention after a steep selloff, with traders debating whether the decline reflects profit-taking and broader weakness in AI stocks or deeper concerns about valuation and share dilution from funding expansion. Some see the pullback as a buying opportunity based on optical-transceiver demand tied to AI data centers, while others expect further downside and are waiting for a clearer bottom.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

A sharp rise in volatility is drawing attention to UVIX, with traders pointing to US-Iran tensions, rising oil and bond yields, and a possible shift toward VIX futures backwardation as potential drivers. Some see the move as a hedge against further market stress, while others warn that UVIXs leveraged structure and decay can erode gains if volatility subsides.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is caught in a broader semiconductor and AI-stock selloff, with traders citing CEO Hock Tans comments about AI investment risk and capital constraints as adding to worries over the sustainability of data-center spending. The community is split between bearish traders blaming the remarks and expecting more downside, and bulls who see sector-wide weakness and view the pullback as a buying opportunity.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grumman is drawing attention amid a rebound and broader strength in defense stocks, with traders pointing to defense-spending expectations, its contract backlog and programs such as the B-21. Dip buyers see long-term demand support, while skeptics remain concerned about the stocks recent weakness and program execution and margins.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs proposed index rules that could exclude Strategy are driving concern about forced selling by index-tracking funds and weighing on shares, alongside Bitcoin weakness. Traders are split between expecting further downside and arguing the potential outflows are limited or already priced in, with some buying the dip.

Tidal Trust II - YieldMax Semiconductor Portfolio Option Income ETF

YieldMax Semiconductor Portfolio Option Income ETF

CHPY is drawing attention amid a sharp pullback in semiconductor stocks and broader tech weakness, which traders say is weighing on the ETFs share price. Many are accumulating and emphasizing its weekly income, while others worry about further declines and whether distributions can offset potential NAV erosion.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X ETF

SOXS has surged amid renewed weakness in semiconductor shares and trader concerns that AI spending may not justify lofty expectations. Some traders expect more downside in chips, while others anticipate a rebound and caution that SOXSs daily leverage and decay make it risky to hold.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBios Radiopharmaceutical Therapy, in Patients with GEP-NETs

Bristol Myers Squibb (NYSE: BMY) today announced positive topline results from the planned interim analysis of the ACTION-1 trial (NCT05477576) conducted by RayzeBio, Inc., a Bristol Myers Squibb company. The study met the primary endpoint with a statistically significant and clinically meaningful...

Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint

Bristol Myers Squibb (NYSE: BMY) today announced topline results from the pivotal Phase 3 ALOFT-IPF trial evaluating the efficacy, safety and tolerability of admilparant, a potential first-in-class, orally administered, potent and selective lysophosphatidic acid receptor 1 (LPA1) antagonist, in...

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3 EXCALIBER-RRMM Study Bristol Myers Squibb (NYSE: BMY) today...

Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale

Key PointsJohnson & Johnson generates consistently higher quarterly revenue than Bristol-Myers Squibb, maintaining a clear lead in total dollars over the entire observed eight-quarter period without any interruption...

Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement

Bristol Myers Squibb (NYSE: BMY) today announced the expansion of Champions in Care, the company's initiative honoring healthcare professionals (HCPs), first launched in 2025. Now in its second year, the campaign builds on its inaugural effort that celebrated HCPs across therapeutic areas through...

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibbs CAMZYOS (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved CAMZYOS (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in adults and pediatric patients weighing 30 kg...

Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb (NYSE: BMY) today announced first time presentation of results from the prespecified analysis of the pivotal Phase 3 EXCALIBER-RRMM trial (NCT04975997) evaluating ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone (ZDd) versus daratumumab, bortezomib, and...

Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026

Bristol Myers Squibb (NYSE: BMY) will announce results for the third quarter of 2026 on Thursday, October 29, 2026. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET.Investors and the general public are invited to...

Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years

Bristol Myers Squibb (NYSE: BMY) today announced positive results through two years of treatment from the Phase 3 POETYK PsA-2 study, including its open-label extension (OLE), showing durable efficacy and a consistent safety profile for Sotyktu (deucravacitinib) in adults with active psoriatic...

Bristol Myers Squibb Announces Dividend

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on November 2, 2026, to stockholders of record at the close of business...

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

CELG Celgene Corporation

Latest CELG News